Acorda Therapeutics, Inc.

Andrew R Blight

Ron Cohen

Lawrence Marinucci

Elliott A Gruskin

Anthony O Caggiano

Tom J Parry

Michael P Zimber

Thomas C Wessel

Jennifer F Iaci

Jacob D Runyan

Herbert R Heney Iii

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

Sustained release aminopyridine composition

Method of using sustained release aminopyridine compositions

Growing community of inventors

Mahopac, NY, United States of America

Andrew R Blight